ArticleOpen heart2025
Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.
Article in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data.Current cardiology reports · 2025Review
- Cardiac myosin inhibitors: a silver lining for an old disease.Open heart · 2025Article
- Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is characterised by abnormal thickening of ventricular myocardium. Left ventricular outflow tract (LVOT) obstruction occurs in up to 70% of patients, causing progressive symptoms, heart failure and mortality. Mavacamten, the first targeted therapy for obstructive HCM (oHCM), was approved for use in the UK in 2024. We present data from the early experience with mavacamten treatment for oHCM in three UK centres and describe different clinical pathways.
methodsAll patients with symptomatic oHCM eligible for mavacamten therapy were included. Eligibility criteria included New York Heart Association (NYHA) class II-III symptoms and LVOT gradients >30 mm Hg with normal left ventricular ejection function (LVEF >55%), as per National Institute for Health and Care Excellence guidelines and product literature. Patients underwent CYP2C19 genotyping before treatment, and dosing was adjusted accordingly. Echocardiographic assessments, clinical reviews and biomarker analyses were conducted at weeks 0, 4, 8 and 12.
results93 patients were initiated on mavacamten (mean age: 60±13 years; 72% male). The Valsalva LVOT gradient significantly decreased during treatment, from 88.9±31 mm Hg at baseline to 43.8±32.6 mm Hg by week 12, and further to 27.7±22.3 mm Hg on the maintenance dose. NT-proBNP levels also improved markedly, from 689 ng/L (IQR 343-1684 ng/L) at baseline to 171 ng/L (IQR 116-335 ng/L) on the maintenance dose. By week 12, 74% of patients experienced an improvement of at least one NYHA class, increasing to 91% on the maintenance dose. Temporary treatment interruptions occurred in 13 patients; however, no patients required permanent discontinuation of treatment due to a reduced LVEF (<50%). Outcomes were comparable across the three care pathways.
conclusionsMavacamten treatment was associated with significant symptomatic improvement, reduced LVOT gradients and improved biomarker profiles in patients with oHCM. The implementation of clinical services to deliver mavacamten in the UK should not follow a 'one-size-fits-all' approach but rather leverage the unique strengths of each specific centre.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.